ovcar3 cells  (ATCC)

Journal: bioRxiv

Article Title: Autophagy disruption primes CAR-T cell metabolism for sustained rejection of ovarian tumors

doi: 10.1101/2025.10.09.681473

Figure Lengend Snippet: ATG5 -knockout CAR-T cells exhibit immediate and long-lasting tumor control in vivo . NSG mice were subcutaneously implanted with 5×10 6 OVCAR3 tumor cells on the left flank. ATG5 -integrated (n=8) or AAVS1 -integrated (n=7) were intravenously administered 46 days after tumor implantation. Tumors were measured twice per week using digital calipers, and mice were euthanized upon reaching humane endpoint (tumor area greater than 160mm 2 ) or at termination of study (125 days after CAR-T infusion). (A) Growth curve showing tumor area over time following treatment with 4×10 6 ATG5 -integrated (red) or AAVS1 -integrated (black) CAR-T cells (one line = one mouse). (B-C) Scatter plots showing average tumor area for the first 17 days of the experiment shown in (A). Solid lines indicate the line of best fit for each group. Error bars represent +/-SEM. (D) Kaplan-Meier survival curve for the experiment shown in (A). Significance was determined by log-rank test: *p < 0.05.

Article Snippet: OVCAR3 human ovarian cancer cells (HTB-161, ATCC) were grown in ATCC-formulated RPMI 1640 (Gibco) supplemented with 20% FBS, 0.01 mg/mL bovine insulin (Sigma), and 1% penicillin-streptomycin.

Techniques: Knock-Out, Control, In Vivo, Tumor Implantation